» Articles » PMID: 33503805

Estrogen Receptor Signaling Pathways Involved in Invasion and Colony Formation of Androgen-Independent Prostate Cancer Cells PC-3

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2021 Jan 28
PMID 33503805
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Castration-resistant prostate cancer (CRPC) is an advanced and androgen-independent form of prostate cancer. Recent studies of rapid actions mediated by estrogen in the prostate and its relationship with CRPC are emerging. We have previously shown that estrogen receptor (ER) promotes migration and invasion of the androgen-independent prostate cancer cells PC-3, but the signaling pathways involved in these events remain to be elucidated. Therefore, this study aimed to analyze the role of ERα and ERβ in the activation of SRC, and the involvement of SRC and PI3K/AKT on invasion and colony formation of the PC-3 cells. Our results showed that the activation of ERα (using ERα-selective agonist PPT) and ERβ (using ERβ-selective agonist DPN) increased phosphorylation of SRC in PC-3 cells. In the presence of the selective inhibitor for SRC-family kinases PP2, the effects of DPN and PPT on transmigration and soft agar colony formation assays were decreased. Furthermore, SRC is involved in the expression of the non-phosphorylated β-catenin. Finally, using PI3K specific inhibitor Wortmannin and AKT inhibitor MK2206, we showed that PI3K/AKT are also required for invasion and colony formation of PC-3 cells simulated by ER. This study provides novel insights into molecular mechanisms of ER in PC-3 cells by demonstrating that ER, located outside the cell nucleus, activates rapid responses molecules, including SRC and PI3K/AKT, which enhance the tumorigenic potential of prostate cancer cells, increasing cell proliferation, migration, invasion, and tumor formation.

Citing Articles

Implications of hormonal carcinogenesis for transgender and gender-diverse people undergoing gender-affirming hormone therapy: an up-to-date review.

Leone A, Bonadonna S, Cassani C, Barcellini A, Sirico M, Tagliaferri B BMJ Oncol. 2025; 3(1):e000330.

PMID: 39886120 PMC: 11235029. DOI: 10.1136/bmjonc-2024-000330.


Involvement of Sex Hormones and Their Receptors in the Pathogenesis of Classic Kaposi's Sarcoma in Xinjiang.

Wei M, Jiang X, Bian Y, Fan J Skin Res Technol. 2024; 30(10):e70086.

PMID: 39349354 PMC: 11442020. DOI: 10.1111/srt.70086.


The Pros and Cons of Estrogens in Prostate Cancer: An Update with a Focus on Phytoestrogens.

Figueira M, Carvalho T, Macario-Monteiro J, Cardoso H, Correia S, Vaz C Biomedicines. 2024; 12(8).

PMID: 39200101 PMC: 11351860. DOI: 10.3390/biomedicines12081636.


The Role of Estrogen Receptors in Health and Disease.

Pakdel F Int J Mol Sci. 2023; 24(14).

PMID: 37511113 PMC: 10378944. DOI: 10.3390/ijms241411354.


Diagnostic and Therapeutic Approaches for Glioblastoma and Neuroblastoma Cancers Using Chlorotoxin Nanoparticles.

Boltman T, Meyer M, Ekpo O Cancers (Basel). 2023; 15(13).

PMID: 37444498 PMC: 10341066. DOI: 10.3390/cancers15133388.


References
1.
Kim R, Bae E, Hong Y, Hong J, Kim N, Ahn H . PTEN loss-mediated Akt activation increases the properties of cancer stem-like cell populations in prostate cancer. Oncology. 2014; 87(5):270-9. DOI: 10.1159/000363186. View

2.
Chen F, Wu J, Teng J, Li W, Zheng J, Bai J . HCRP-1 regulates cell migration, invasion and angiogenesis via Src/ FAK signaling in human prostate cancer. Int J Biol Sci. 2020; 16(2):342-352. PMC: 6949154. DOI: 10.7150/ijbs.38112. View

3.
Heinlein C, Chang C . Androgen receptor in prostate cancer. Endocr Rev. 2004; 25(2):276-308. DOI: 10.1210/er.2002-0032. View

4.
Yu L, Wang L, Kim J, Mao C, Shapiro D . Src couples estrogen receptor to the anticipatory unfolded protein response and regulates cancer cell fate under stress. Biochim Biophys Acta Mol Cell Res. 2020; 1867(10):118765. PMC: 7653967. DOI: 10.1016/j.bbamcr.2020.118765. View

5.
Vellky J, Ricke W . Development and prevalence of castration-resistant prostate cancer subtypes. Neoplasia. 2020; 22(11):566-575. PMC: 7522286. DOI: 10.1016/j.neo.2020.09.002. View